Products from BPS Bioscience require a minimum order value above 400€
Background: Mouse IL-13 is produced primarily by activated Th2 cells. Human IL-13 is expressed in activated T- helper cells (resembling Th0, Th1, Th2), and T-cells expressing CD8. The alpha chain of the IL1-3 receptor has weak binding activity for IL-13. High affinity receptors are formed when the receptor alpha chains of IL-13 and IL-4 receptors are coexpressed. The receptors for IL-13 and IL-4 share a common gamma subunit that is found also in the IL-2 receptor. Different IL-13 receptor structures have been shown to exist on various cell types and the IL-13 receptor may share more than one component with IL-4 receptor. IL-13 down-modulates macrophage activity, reducing the production of pro-inflammatory cytokines and chemokines in response to IFN-gamma or bacterial lypopolysaccharides. IL-13 enhances the production of the IL-1 receptor antagonist IL-1ra. IL-13 also decreases the production of nitric oxide by activated macrophages, leading to a decrease in parasiticidal activity. IL-13 induces differentiation of human monocytes, enhances survival time in culture, and also induces differentiation and proliferation and Isotype switching in B-cells.
Description: Lebrikizumab (TNX-650) is an IgG4 humanized anti-interleukin-13 (IL-13) mAb with anti-itch effects that specifically binds to IL-13 in a non-receptor binding domain and inhibits its function. Lebrikizumab inhibits the IL-13 driven Th2 inflammatory response and blocks the signaling of IL-4Rα/IL-13Rα1. Lebrikizumab can be used for the research of asthma, atopic dermatitis and neuroinflammatory diseases1,2,3.
Format: Aqueous buffer solution.
Formulation: Supplied as a 0.22 μm filtered solution in PBS, pH 7.4.
Host Cell Line: CHO
Purity: ≥90%
Storage Stability: Store at -80°C for 2 years. Aliquots should be stored at the same temperature after first use to avoid multiple freeze-thaws.
Target: IL-13
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
References: 1. Jonathan Corren, et al., 2011N Engl J Med. 365(12): 1088-98. 2. Loh TY, et al., 2020 J Asthma Allergy. 13:109-114. 3. Miron Y, et al., 2022 J Allergy Clin Immunol. 150(3): 690-700.
English
Deutsch
